IS7880A - Efnasambönd sem hamla gegn virkni kalkviðtaka - Google Patents
Efnasambönd sem hamla gegn virkni kalkviðtakaInfo
- Publication number
- IS7880A IS7880A IS7880A IS7880A IS7880A IS 7880 A IS7880 A IS 7880A IS 7880 A IS7880 A IS 7880A IS 7880 A IS7880 A IS 7880A IS 7880 A IS7880 A IS 7880A
- Authority
- IS
- Iceland
- Prior art keywords
- compounds
- receptor activity
- calcium receptor
- inhibit calcium
- inhibit
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C217/28—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines
- C07C217/30—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C217/28—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines
- C07C217/30—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring
- C07C217/32—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C217/28—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines
- C07C217/30—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring
- C07C217/32—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted
- C07C217/34—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted by halogen atoms, by trihalomethyl, nitro or nitroso groups, or by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Nutrition Science (AREA)
- Immunology (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US42910502P | 2002-11-26 | 2002-11-26 | |
PCT/US2003/037461 WO2004047751A2 (en) | 2002-11-26 | 2003-11-25 | Calcilytic compounds |
Publications (2)
Publication Number | Publication Date |
---|---|
IS7880A true IS7880A (is) | 2005-06-02 |
IS2897B IS2897B (is) | 2014-09-15 |
Family
ID=32393505
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IS7880A IS2897B (is) | 2002-11-26 | 2005-06-02 | Efnasambönd sem hamla gegn virkni kalkviðtaka |
Country Status (33)
Country | Link |
---|---|
US (6) | US7514473B2 (is) |
EP (1) | EP1569892B1 (is) |
JP (1) | JP4489597B2 (is) |
KR (2) | KR20050086786A (is) |
CN (1) | CN1325466C (is) |
AP (1) | AP2113A (is) |
AR (1) | AR042132A1 (is) |
AU (1) | AU2003291157C1 (is) |
BR (1) | BR0316544A (is) |
CA (1) | CA2507226C (is) |
CO (1) | CO5570664A2 (is) |
CY (1) | CY1113083T1 (is) |
DK (1) | DK1569892T3 (is) |
EA (1) | EA009603B1 (is) |
ES (1) | ES2388277T3 (is) |
HK (1) | HK1082914A1 (is) |
IL (1) | IL168704A (is) |
IS (1) | IS2897B (is) |
MA (1) | MA27528A1 (is) |
MX (1) | MXPA05005574A (is) |
MY (1) | MY143244A (is) |
NO (1) | NO332304B1 (is) |
NZ (1) | NZ540275A (is) |
OA (1) | OA12962A (is) |
PE (1) | PE20040845A1 (is) |
PL (1) | PL211571B1 (is) |
PT (1) | PT1569892E (is) |
SI (1) | SI1569892T1 (is) |
TW (1) | TWI316511B (is) |
UA (1) | UA81642C2 (is) |
UY (1) | UY28089A1 (is) |
WO (1) | WO2004047751A2 (is) |
ZA (1) | ZA200504104B (is) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI316511B (en) * | 2002-11-26 | 2009-11-01 | Smithkline Beecham Corp | Calcilytic compounds |
JP2007522148A (ja) * | 2004-02-06 | 2007-08-09 | スミスクライン・ビーチャム・コーポレイション | カルシウム受容体アンタゴニスト化合物 |
TW200845956A (en) * | 2006-12-18 | 2008-12-01 | Smithkline Beecham Corp | Calcilytic compounds |
WO2009148052A1 (ja) | 2008-06-05 | 2009-12-10 | 旭化成ファーマ株式会社 | スルホンアミド化合物及びその用途 |
CN102307847A (zh) * | 2008-12-24 | 2012-01-04 | 第一三共株式会社 | 茚满基化合物 |
GB201217330D0 (en) | 2012-09-28 | 2012-11-14 | Univ Cardiff | Therapeutic for treating inflammatory lung disorders |
WO2015196205A1 (en) * | 2014-06-20 | 2015-12-23 | Glaxosmithkline Llc | Method of using calcilytic compounds to treat diseases of abnormal glucose or insulin levels |
Family Cites Families (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE298506C (is) | ||||
US643656A (en) * | 1898-09-03 | 1900-02-20 | Francis Keil | Mold for lock-cylinders and key-hubs. |
ES421076A1 (es) | 1973-12-01 | 1976-04-01 | Andreu Sa Dr | Procedimiento para la obtencion de 1-ariloxi-3-aralquilami-no-2-propanoles. |
ES442062A1 (es) | 1975-10-24 | 1977-04-01 | Andreu Sa Dr | Procedimiento para la obtencion de 1-ariloxi-2-hidroxi-3- alquilaminopropanos. |
DE2644833A1 (de) | 1976-10-05 | 1978-04-20 | Boehringer Sohn Ingelheim | Neue 1-aryloxy-2-hydroxy-3-alkylenaminopropane und verfahren zu ihrer herstellung |
CH618335A5 (is) * | 1977-05-31 | 1980-07-31 | Arnegger Richard E | |
US4234595A (en) * | 1977-07-13 | 1980-11-18 | Mead Johnson & Company | 3-Indolyl-tertiary butylaminopropanols |
IL56369A (en) | 1978-01-20 | 1984-05-31 | Erba Farmitalia | Alpha-phenoxybenzyl propanolamine derivatives,their preparation and pharmaceutical compositions comprising them |
IT1101724B (it) * | 1978-12-05 | 1985-10-07 | Erba Carlo Spa | Derivati morfolinici e fenossiprofanolaminici e procedimento per la loro preparazione |
GB2014968A (en) | 1978-02-24 | 1979-09-05 | Pearson J | Article handling apparatus |
US4495352A (en) | 1979-02-13 | 1985-01-22 | Mead Johnson & Company | Heterocyclic substituted aryloxy 3-indolyl-tertiary butylaminopropanols |
ES480066A1 (es) | 1979-04-28 | 1980-04-01 | Especialid Latin Medicam Unive | Procedimiento de obtencion de 1-4-cloro-&,&-dimetil-benceno-etanamino-2-oxi-3 ariloxi propanos. |
DE3544172A1 (de) | 1985-12-13 | 1987-06-19 | Lentia Gmbh | Neue kristalline salze von aryloxy-propanolaminen, verfahren zu ihrer herstellung und ihre verwendung |
FR2601008B1 (fr) | 1986-07-03 | 1990-03-30 | Sanofi Sa | Procede de synthese stereospecifique de derives de l'indole |
DD298506A5 (de) * | 1988-12-30 | 1992-02-27 | Ernst-Moritz-Arndt-Universitaet Greifswald,De | Verfahren zur herstellung halogensubstituierter 1-phenoxy-3-alkylamino-propan-2-ole |
DE4040186A1 (de) | 1989-12-20 | 1991-06-27 | Hoechst Ag | Hypoglykaemisch aktive propandiolaminderivate mit insulin-aehnlicher wirkung und deren verwendung, neue propandiolaminderivate, diese substanzen enthaltende pharmazeutische zubereitungen und ihre verwendung zur behandlung von krankheiten |
HN1996000101A (es) * | 1996-02-28 | 1997-06-26 | Inc Pfizer | Terapia combinada para la osteoporosis |
JP2001501584A (ja) | 1996-04-09 | 2001-02-06 | エヌピーエス・ファーマシウティカルズ・インコーポレイテッド | カルシリチック化合物 |
US6818660B2 (en) | 1996-04-09 | 2004-11-16 | Nps Pharmaceuticals, Inc. | Calcilytic compounds |
US20020019440A1 (en) | 1996-11-05 | 2002-02-14 | Virbac Sa | Aryloxypropanolamine derivatives, method of preparation and applications thereof |
TW483881B (en) | 1996-12-03 | 2002-04-21 | Nps Pharma Inc | Calcilytic compounds |
US7202261B2 (en) | 1996-12-03 | 2007-04-10 | Nps Pharmaceuticals, Inc. | Calcilytic compounds |
CA2285556A1 (en) | 1997-04-04 | 1998-10-15 | Smithkline Beecham Corporation | Calcilytic compounds |
UY24949A1 (es) | 1997-04-08 | 2001-04-30 | Smithkline Beecham Corp | Compuestos calcilíticos |
DE19913753A1 (de) | 1998-04-01 | 1999-10-07 | Mannesmann Rexroth Ag | Verfahren zur Bildung des Mittelwertes |
PE20000415A1 (es) | 1998-04-08 | 2000-05-21 | Smithkline Beecham Corp | Compuestos calciliticos |
AR014975A1 (es) | 1998-04-08 | 2001-04-11 | Nps Pharma Inc | Compuestos calciliticos, una composicion farmaceutica que los comprende, y el uso de los mismos para la fabricacion de un medicamento |
US6291459B1 (en) | 1998-08-12 | 2001-09-18 | Smithkline Beecham Corporation | Calcilytic compounds |
JP2002522532A (ja) | 1998-08-12 | 2002-07-23 | スミスクライン・ビーチャム・コーポレイション | カルシウム分解化合物 |
PE20001456A1 (es) | 1999-02-02 | 2001-01-28 | Smithkline Beecham Corp | Compuestos calcioliticos |
AU6050000A (en) | 1999-07-22 | 2001-02-13 | Eli Lilly And Company | Improved method of treating type ii diabetes and obesity |
CO5180628A1 (es) | 1999-07-31 | 2002-07-30 | Smithkline Beecham Corp | Compuestos calcioliticos |
MY159417A (en) | 2000-01-24 | 2017-01-13 | Smithkline Beecham Corp | Calcilytic compounds |
US20030018203A1 (en) | 2002-07-17 | 2003-01-23 | Largo Maria Amparo | Calcilytic compounds |
PL365703A1 (en) | 2000-07-21 | 2005-01-10 | Smithkline Beecham Corporation | Calcilytic compounds |
AU2002230579A1 (en) | 2000-10-25 | 2002-05-06 | Smithkline Beecham Corp | Calcilytic compounds |
BR0114884A (pt) | 2000-10-25 | 2004-07-06 | Smithkline Beecham Corp | Compostos calcilìticos |
WO2002072760A2 (en) | 2001-03-08 | 2002-09-19 | Smithkline Beecham Corporation | Pcra helicase inhibitors |
US6864267B2 (en) | 2001-07-16 | 2005-03-08 | Smithkline Beecham Corporation | Calcilytic compounds |
TWI316511B (en) | 2002-11-26 | 2009-11-01 | Smithkline Beecham Corp | Calcilytic compounds |
WO2004092120A2 (en) | 2003-04-07 | 2004-10-28 | Nps Pharmaceuticals, Inc. | Pyrimidinone compounds as calcilytics |
AU2004266705A1 (en) | 2003-08-20 | 2005-03-03 | Nitromed, Inc. | Nitrosated and nitrosylated cardiovascular compounds, compositions and methods of use |
WO2005030746A1 (en) | 2003-09-24 | 2005-04-07 | Glaxo Group Limited | Calcilytic compounds |
TW200524892A (en) | 2003-09-24 | 2005-08-01 | Glaxo Group Ltd | Calcilytic compounds |
US20080234370A1 (en) | 2004-02-06 | 2008-09-25 | Marquis Robert W | Calcilytic Compounds |
NL1025457C1 (nl) | 2004-02-11 | 2005-08-12 | Rudolf Johannes Gerardus Hoorn | Haspelrem. |
WO2006052899A2 (en) | 2004-11-08 | 2006-05-18 | Nitromed, Inc. | Nitrosated and nitrosylated compounds, compositions and methods for the treatment of ophthalmic disorders |
EP1846380A4 (en) | 2005-01-21 | 2010-02-17 | Nicox Sa | HETEROCYCLIC NITROGEN MONOXIDE DONOR COMPOSITIONS CONTAINING CARDIOVASCULAR COMPOUNDS, AND METHODS OF USING THE SAME |
-
2003
- 2003-11-24 TW TW092132853A patent/TWI316511B/zh not_active IP Right Cessation
- 2003-11-24 AR ARP030104333A patent/AR042132A1/es not_active Application Discontinuation
- 2003-11-24 UY UY28089A patent/UY28089A1/es unknown
- 2003-11-24 MY MYPI20034511A patent/MY143244A/en unknown
- 2003-11-25 MX MXPA05005574A patent/MXPA05005574A/es active IP Right Grant
- 2003-11-25 KR KR1020057009379A patent/KR20050086786A/ko not_active Application Discontinuation
- 2003-11-25 US US10/536,416 patent/US7514473B2/en not_active Expired - Fee Related
- 2003-11-25 NZ NZ540275A patent/NZ540275A/en not_active IP Right Cessation
- 2003-11-25 ES ES03783752T patent/ES2388277T3/es not_active Expired - Lifetime
- 2003-11-25 UA UAA200505005A patent/UA81642C2/ru unknown
- 2003-11-25 AU AU2003291157A patent/AU2003291157C1/en not_active Ceased
- 2003-11-25 PT PT03783752T patent/PT1569892E/pt unknown
- 2003-11-25 WO PCT/US2003/037461 patent/WO2004047751A2/en active Application Filing
- 2003-11-25 EP EP03783752A patent/EP1569892B1/en not_active Expired - Lifetime
- 2003-11-25 CA CA2507226A patent/CA2507226C/en not_active Expired - Fee Related
- 2003-11-25 SI SI200332179T patent/SI1569892T1/sl unknown
- 2003-11-25 OA OA1200500152A patent/OA12962A/en unknown
- 2003-11-25 PL PL376965A patent/PL211571B1/pl unknown
- 2003-11-25 DK DK03783752.3T patent/DK1569892T3/da active
- 2003-11-25 AP AP2005003320A patent/AP2113A/xx active
- 2003-11-25 KR KR1020117025893A patent/KR101142697B1/ko not_active IP Right Cessation
- 2003-11-25 BR BR0316544-2A patent/BR0316544A/pt active Search and Examination
- 2003-11-25 CN CNB2003801092068A patent/CN1325466C/zh not_active Expired - Fee Related
- 2003-11-25 JP JP2004555635A patent/JP4489597B2/ja not_active Expired - Fee Related
- 2003-11-25 PE PE2003001196A patent/PE20040845A1/es not_active Application Discontinuation
- 2003-11-25 EA EA200500878A patent/EA009603B1/ru not_active IP Right Cessation
-
2005
- 2005-05-19 IL IL168704A patent/IL168704A/en not_active IP Right Cessation
- 2005-05-23 MA MA28294A patent/MA27528A1/fr unknown
- 2005-05-24 CO CO05050416A patent/CO5570664A2/es active IP Right Grant
- 2005-06-02 IS IS7880A patent/IS2897B/is unknown
- 2005-06-22 NO NO20053071A patent/NO332304B1/no not_active IP Right Cessation
-
2006
- 2006-02-07 ZA ZA200504104A patent/ZA200504104B/en unknown
- 2006-03-02 HK HK06102773.3A patent/HK1082914A1/xx not_active IP Right Cessation
-
2009
- 2009-02-26 US US12/393,284 patent/US7829594B2/en not_active Expired - Fee Related
-
2010
- 2010-09-30 US US12/894,644 patent/US8399517B2/en not_active Expired - Fee Related
-
2012
- 2012-09-03 CY CY20121100784T patent/CY1113083T1/el unknown
-
2013
- 2013-02-11 US US13/764,126 patent/US8586631B2/en not_active Expired - Fee Related
- 2013-11-01 US US14/069,447 patent/US8980950B2/en not_active Expired - Fee Related
-
2015
- 2015-03-06 US US14/640,711 patent/US9227914B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE50309032D1 (de) | Fungizide wirkstoffkombinationen | |
ATE368042T1 (de) | Cephemverbindungen | |
IS7471A (is) | Ný efnasambönd | |
IL205600A0 (en) | Benzimidazolone compounds having 5-ht4 receptor agonistic activity | |
NO20052914D0 (no) | Terapeutiske forbindelser | |
IS7801A (is) | Púrín efnasambönd og notkun þeirra sem kannabinóíð viðtaka bindla | |
IS8313A (is) | Sýklískar afleiður sem stillar kemókínviðtakavirkni | |
IS7362A (is) | Kínasólín efnasambönd | |
DK1585876T3 (da) | Gulvplade | |
DE60317967D1 (de) | Umhüllte feste Darreichungsform | |
IL163931A0 (en) | Amino-methyl substituted tetracyline compounds | |
DE50308694D1 (de) | Bestrahlungsger t | |
IS7381A (is) | Efnasambönd | |
IS7827A (is) | Ný efnasambönd | |
ATE544762T1 (de) | Calcium rezeptor modulatoren | |
IS2897B (is) | Efnasambönd sem hamla gegn virkni kalkviðtaka | |
IS8172A (is) | N-úreidóalkýl-piperídín sem stillar kemókínviðtakavirkni | |
DE60327447D1 (de) | Pflaster | |
NO20045659L (no) | Forbindelser | |
DE60332816D1 (de) | Nk1-antagonisten | |
DE60312100D1 (de) | Kabelbaum | |
ITGE20020042A1 (it) | Letto per lungo-degenti | |
FI20020392A0 (fi) | Järjestely urinaalia varten | |
IS7739A (is) | N-úreidóalkýl-píperidín sem stillar kemókínviðtakavirkni | |
GB2393459B (en) | Joist hanger |